Sano Rie, Nakajima Tamiko, Takahashi Yoichiro, Kubo Rieko, Kobayashi Momoko, Takahashi Keiko, Takeshita Haruo, Ogasawara Kenichi, Kominato Yoshihiko
From the Department of Legal Medicine, Gunma University Graduate School of Medicine, Maebashi, 371-8511 Japan,
From the Department of Legal Medicine, Gunma University Graduate School of Medicine, Maebashi, 371-8511 Japan.
J Biol Chem. 2016 Oct 21;291(43):22594-22606. doi: 10.1074/jbc.M116.730655. Epub 2016 Sep 1.
The human ABO blood group system is of great importance in blood transfusion and organ transplantation. The ABO system is composed of complex carbohydrate structures that are biosynthesized by A- and B-transferases encoded by the ABO gene. However, the mechanisms regulating ABO gene expression in epithelial cells remain obscure. On the basis of DNase I-hypersensitive sites in and around ABO in epithelial cells, we prepared reporter plasmid constructs including these sites. Subsequent luciferase assays and histone modifications indicated a novel positive regulatory element, designated the +22.6-kb site, downstream from ABO, and this was shown to enhance ABO promoter activity in an epithelial cell-specific manner. Expression of ABO and B-antigen was reduced in gastric cancer KATOIII cells by biallelic deletion of the +22.6-kb site using the CRISPR/Cas9 system. Electrophoretic mobility shift assay and chromatin immunoprecipitation assay demonstrated that the site bound to an epithelial cell-specific transcription factor, Elf5. Mutation of the Ets binding motifs to abrogate binding of this factor reduced the regulatory activity of the +22.6-kb site. Furthermore, ELF5 knockdown with shRNA reduced both endogenous transcription from ABO and B-antigen expression in KATOIII cells. Thus, Elf5 appeared to be involved in the enhancer potential of the +22.6-kb site. These results support the contention that ABO expression is dependent upon a downstream positive regulatory element functioning through a tissue-restricted transcription factor, Elf5, in epithelial cells.
人类ABO血型系统在输血和器官移植中具有重要意义。ABO系统由复杂的碳水化合物结构组成,这些结构由ABO基因编码的A和B转移酶生物合成。然而,上皮细胞中调节ABO基因表达的机制仍不清楚。基于上皮细胞中ABO及其周围的DNase I超敏位点,我们制备了包含这些位点的报告质粒构建体。随后的荧光素酶测定和组蛋白修饰表明,在ABO下游有一个新的正调控元件,命名为+22.6-kb位点,并且该位点以上皮细胞特异性方式增强ABO启动子活性。使用CRISPR/Cas9系统对+22.6-kb位点进行双等位基因缺失后,胃癌KATOIII细胞中ABO和B抗原的表达降低。电泳迁移率变动分析和染色质免疫沉淀分析表明,该位点与上皮细胞特异性转录因子Elf5结合。将Ets结合基序突变以消除该因子的结合,降低了+22.6-kb位点的调控活性。此外,用shRNA敲低ELF5可降低KATOIII细胞中ABO的内源性转录和B抗原的表达。因此,Elf5似乎参与了+22.6-kb位点的增强子潜能。这些结果支持了这样的观点,即ABO表达依赖于一个下游正调控元件,该元件通过组织限制性转录因子Elf5在上皮细胞中发挥作用。